$170 | Single User
$340 | Site License
$510 | Global License

Competitor Analysis: Kallikrein Inhibitors 2017 [Report Updated: 23-04-2017]

Published by La Merie: 23 Apr 2017 | 95055 | In Stock

Introduction

Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists


The present Competitive Intelligence report about Kallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel approaches for prophylaxis and treatment of hereditary angioedema (HAE) as of June 2014. Inhibitors of kallikrein and antagonists of the bradykinin receptors are based on small molecules, antibodies, proteins, peptides as well as RNA and their use is being extended to other diseases.


Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in research and development of small molecule, antibody, protein, peptide and oligonucleotide inhibitors or antagonists kallikrein or the bradykinin receptor, respectively. In addition, the report lists company-specific R&D pipelines of kallikerein inhibitors & bradykinin receptor antagonists. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents
for Competitor Analysis: Kallikrein Inhibitors 2017 [Report Updated: 23-04-2017]

  • Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists

    Table of Contents

    1.         Kallikrein Inhibitors

    2.         Bradykinin Receptor Antagonists

    3.         Corporate Kallikrein Inhibitor & Bradykinin Receptor Antagonist R&D Pipelines

Additional Details

Publisher

La Merie

Publisher Information

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Reference

95055 | LMCA0139

Number of Pages

17

Report Format

PDF

La Merie Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Compet...
01 Jun 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel a...
01 May 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitiv...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 UpdateThis Competitive...
01 May 2016 by La Merie USD $280 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) familyThe Compet...
17 Jan 2016 by La Merie USD $225 More Info
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
Scope Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Vie...
11 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
05 Mar 2014 by FirstWord Pharma USD $695 More Info

This report is published by La Merie

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Download Free Report Summary PDF

Competitor Analysis: Kallikrein Inhibitors 2017 [Report Updated: 23-04-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data